glutathione and parkinsons disease Dysregulation of Homeostasis in Neurodegenerative Diseases Glutathione and Parkinson's disease: Is

Description

Glutathione transporter as a target for brain-targeting drug delivery The first report using GSH as a brain targeting agent was from Wang et al

This research peptide has generated significant buzz due to its unprecedented weight loss potential in early-phase trials

[DOI] [PubMed] [Google Scholar] 79.Imeri L, Opp MR

Glutathione is involved in maintaining the proper equilibrium of the reduced form of the other reduction potential carrier - NADPH

HIV: Human immunodeficiency virus HNF-1: Hepatocyte nuclear factor 1 HOGO: Human Genome Organisation 5-HT: 5-Hydroxytryptamine receptors IC 50 : Half maximal inhibitory concentration ISEF: Intersystem extrapolation factor IVIVE: In vitro - in vivo extrapolation kDa: Kilodalton K i : Inhibition constant K m : Michaelis-Menten constant LC-MS/MS: Liquid chromatography with tandem mass spectrometry Log P: Lipophilicity MDRs: Medium-chain dehydrogenases/reductases 4-MP: 4-Methylpyrazole mRNA: Messenger ribonucleic acid NAD + : Nicotinamide adenine dinucleotide NADH: Reduced form of nicotinamide adenine dinucleotide NASH: Nonalcoholic steatohepatitis NBP: Butylphthalide or l-3- n -butylphthalide NF-1: Nuclear factor-1 NSAID: Anti-inflammatory drug SSRI: Selective serotonin reuptake inhibitor OCD: Obsessive compulsive disorder PEG: Polyethylene glycols PK: Pharmacokinetics P-gp: P-glycoprotein RAF: Relative activity factor SGLT2: Sodium-glucose co-transporter 2 T2DM: Type 2 diabetes mellitus UGT: UDP-glucuronosyltransferase USF: Upstream stimulatory factor References Edenberg HJ, McClintick JN